Skip to content

Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
expert-review-logo

Profile of the SeptiCyte™ LAB gene expression assay to diagnose infection in critically ill patients.

Sepsis is a severe and frequently occurring clinical syndrome, caused by the inflammatory response to infections. Recent studies on the human transcriptome during sepsis have yielded several gene-expression assays that might assist physicians during clinical assessment of patients suspected of sepsis. SeptiCyte™ LAB (Immunexpress, Seattle, WA) is the first gene...
soundcloud-logo

Future In A Flash – Rollie Carlson CEO of Immunexpress

As the JP Morgan Healthcare Conference convenes in San Francisco, we’re offering a glimpse into the future of the industry, from the C-suites of the most promising pharma, biopharma, medtech, tech and telehealth companies in the nation. Today we explore the latest trends in rapid diagnostics with Immunexpress CEO, Rollie...
BioCentury-large

Sepset’s Sepsis Signature

BioCentury Senior Writer Michael Leviten discusses gene expression tests that could speed up diagnosis of sepsis.
IDWeek2018

Modeling Improved Patient Management and Hospital Savings with SeptiCyte™ LAB in the Diagnosis of Sepsis at ICU Admission

Background: The ability to accurately diagnose sepsis at ICU admission is key to effective clinical management, patient safety, and efficient hospital resource utilization. Most tests used for sepsis diagnosis, including pathogen detection and host-based biomarker approaches, are lacking in either sensitivity or specificity, resulting in a clinical assumption of sepsis,...
Westwood-One-4C-Logo-Separated

Most People Don’t Know What Sepsis Is

September is Sepsis Awareness Month and part of the problem in fighting sepsis is that most people don’t know what it is, reports Westwood One. However, now there may be a faster way to detect it. Sepsis occurs when the body’s efforts to fight an infection trigger inflammation throughout the...
Immunexpress.com

European and U.S. Patent Allowances Strengthen Immunexpress’ Leading Position in Host-Response Sepsis Diagnostics

Patent Allowances Relate to SeptiCyte™ Technology Using Biomarkers These allowances further reinforce the claims of the core family of patents that support the Company’s gene expression technology in the detection of host response to sepsis SEATTLE, Sept. 24, 2018 – Immunexpress, Inc., today announced the receipt of ‘Notices of Allowance’...
logo-medgadget

Immunexpress Saving Lives with Improved Sepsis Diagnosis: Interview with Rolland Carlson PhD, CEO

Medgadget editor Tom Peach sat down with Dr.Carlson from Immunexpress to hear more about the company’s first FDA-approved sepsis diagnostic test, SeptiCyte, and what the future of sepsis diagnosis and treatment may look like.  
2nd World Sepsis Conference Banner

Immunexpress is proud to be one of the sponsors for the 2nd World Sepsis Conference, Sept 5-6, 2018

"The 2nd World Sepsis Congress will be held on September 5th and 6th, 2018 - free of charge and completely online, so you can participate from wherever you have an internet connection. Over the course of 17 sessions, more than 100 speakers from 30 countries will discuss all aspects of...
Health Leaders

3 Need-to-Know Leaps in Sepsis Care

Rolland Carlson, PhD, CEO of Immunexpress, discusses a different approach to the sepsis battle. Rather than passively chasing pathogens, the Company has developed a test to measure the body's specific immune response to infection by examining biomarkers in the patient's blood.
MedTech Insight

Immunexpress is a finalist for the 2018 MedTech Best Proof-of-Value of an Innovation award

"LONDON – AUGUST 13, 2018 – Informa Pharma Intelligence today announces the finalists for the 2018 Medtech Insight Awards. The diverse group of finalists were chosen by a highly respected independent panel of experts from across the sector." -- Pharma Intelligence https://pharmaintelligence.informa.com/events/awards/medtech-insight-awards-2018
Immunexpress.com

Immunexpress Receives Notice of U.S. Patent Allowance for SeptiCyte™ Technology to Quantify Biomarkers

The allowance complements the Company's growing patent portfolio of gene technology in the detection of host response to sepsis SEATTLE, July 26, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 15/160749, "Validating biomarker...
bioworld-logo

Appointments and advancements – Fayyaz Memon

Immunexpress continues executive team expansion with addition of Fayyaz Memon as VP of Regulatory Affairs & Quality.

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com

Scroll To Top